Alessandro Previtali

1.4k citations
18 papers · 374 indexed · 1 hit paper · h-index 7
Topics
CAR-T cell therapy research (10 papers)Lymphoma Diagnosis and Treatment (6 papers)Biosimilars and Bioanalytical Methods (4 papers)

In The Last Decade

Alessandro Previtali

14 papers receiving 370 citations

Hit Papers

Lisocabtagene maraleucel as second-line therapy for large...2022202620232024202250100150

Peers

Alessandro Previtali
Comparison fields: 5 of 39
  • Oncology 257
  • Pathology and Forensic Medicine 111
  • Hematology 101
  • Molecular Biology 84
  • Immunology 76
Replace David Sermer with:
David Sermer United States
Alessandro Crotta United States
Christine Dehner United States
Houston Holmes United States
Hien Liu United States
Noemi Mergen Germany
Rodica Morariu-Zamfir United States
Edwin Kingsley United States
Raya Mawad United States
Elizabeth Budde United States
Alessandro Previtali relative to David Sermer United States David Sermer's profile →
Citations per field
00.5×3.4×
David Sermer · 1×
Citations per year

Countries citing papers authored by Alessandro Previtali

Since Specialization
Citations

This map shows the geographic impact of Alessandro Previtali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Previtali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Previtali more than expected).

Fields of papers citing papers by Alessandro Previtali

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Previtali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Previtali. The network helps show where Alessandro Previtali may publish in the future.

Co-authorship network of co-authors of Alessandro Previtali

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Previtali. A scholar is included among the top collaborators of Alessandro Previtali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Previtali. Alessandro Previtali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
#WorkIndexed citations
1 1
2 0
3 0
4 0
5 2
6 0
7 17
8 1
9
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM studybreakdown →
186
10 6
11 17
12 64
13 6
14 60
15 3
16 9
17 1
18 1

About Alessandro Previtali

Alessandro Previtali is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology, having authored 18 papers that have together received 374 indexed citations. Recurring topics across this work include CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (6 papers) and Biosimilars and Bioanalytical Methods (4 papers). The work is most often cited by research in Oncology (257 citations), Hematology (101 citations) and Pathology and Forensic Medicine (111 citations). Alessandro Previtali has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Jon Arnason, Pim Mutsaers, Sandrine Montheard, Jeremy S. Abramson, Koji Izutsu, Sami Ibrahimi, Alessandro Crotta, Patrick B. Johnston, Manali Kamdar and Matthew A. Lunning. Their work appears in journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026